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Background: This study was designed to explore the feasibility of replacing the conventional peri-/intratumoural
ultrasound (US)-guided technetium-99m albumin nanocolloid (99mTc-nanocolloid) administration by an injection of
the same tracer guided by a freehand single-photon emission computed tomography (SPECT) device in patients
with non-palpable breast cancer with an iodine-125 (125I) seed as tumour marker, who are scheduled for a sentinel
lymph node biopsy (SLNB). This approach aimed to decrease the workload of the radiology department, avoiding a
second US-guided procedure.
Methods: In ten patients, the implanted 125I seed was primarily localised using freehand SPECT and subsequently verified
by conventional US in order to inject the 99mTc-nanocolloid. The following 34 patients were injected using only
freehand SPECT localisation. In these patients, additional SPECT/CT was acquired to measure the distance
between the 99mTc-nanocolloid injection depot and the 125I seed. In retrospect, a group of 21 patients with
US-guided 99mTc-nanocolloid administrations was included as a control group.
Results: The depth difference measured by US and freehand SPECT in ten patients was 1.6 ± 1.6 mm. In the following
36 125I seeds (34 patients), the average difference between the 125I seed and the centre of the 99mTc-nanocolloid
injection depot was 10.9 ± 6.8 mm. In the retrospective study, the average distance between the 125I seed and the
centre of the 99mTc-nanocolloid injection depot as measured in SPECT/CT was 9.7 ± 6.5 mm and was not significantly
different compared to the freehand SPECT-guided group (two-sample Student's t test, p = 0.52).
Conclusion: We conclude that using freehand SPECT for 99mTc-nanocolloid administration in patients with
non-palpable breast cancer with previously implanted 125I seed is feasible. This technique may improve daily clinical
logistics, reducing the workload of the radiology department.
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The use of mammographic screening in nationwide pro-
grams within western countries has led to an increase in
the number of women with non-palpable breast cancer le-
sions [1,2]. Currently, more than 25% of the radiological
suspicious breast lesions are considered clinically non-
palpable [3]. Accordingly, in many patients, accurate
pre- and intraoperative localisation of these non-palpable
lesions is important for adequate breast-conserving sur-
gery. At present, four different techniques are used to lo-
calise the tumour prior to excision: wire-, ultrasound
(US)-, carbon- and radio-guided (i.e. guided by a radio-
nuclide) localisation [3-5]. When lymph node involve-
ment is undetermined, these approaches are combined
with a sentinel lymph node (SLN) procedure [6,7].
At The Netherlands Cancer Institute, both radio-guided
occult lesion localisation (ROLL) with radioactive
technetium-99m albumin nanocolloid (99mTc-nanocol-
loid) and radioactive seed localisation (RSL) are used
for non-palpable breast tumour localisation during
surgery [8]. In the case of RSL, a 3.7 to 10.7 MBq
iodine-125 seed (125I) with a half-life time of 60 days is
preoperatively implanted into the malignancy using US
guidance in most cases. When the tumour was only
visible on mammography, placement of the 125I seed
was performed under stereotactic guidance. In our in-
stitute, the location of the 125I seed is always confirmed
by an additional mammogram at the day of implan-
tation. Recent studies show advantages when looking
at resection margins, duration of localisation and sur-
gical excision time for RSL or ROLL over wire-based
localisation [3,9-11]. At The Netherlands Cancer Insti-
tute, RSL is a standard procedure, and over 1,000 125I
seeds have been implanted since 2008.
In all patients scheduled for tumour excision, the pro-
cedure is combined with sentinel lymph node biopsy
(SLNB) for regional staging of the disease. This staging
is of great significance for patient outcome, being a pre-
dictor of presence for further metastasis in the axillary
basin [12]. Clinical protocols for this procedure may vary
between institutes because the radiocolloid injection site
for SLNB is still a matter of controversy [13-17]. At The
Netherlands Cancer Institute, the 99mTc-nanocolloid for
SLNB in non-palpable breast cancer is preferably adminis-
tered intratumourally by US guidance, although, in clinical
practice, it turns out to be either peri- or intratumoural.
Peritumoural is defined as the area at least within a radius
of 10 mm to the tumour border. Intratumoural injections
can sometimes result in resistance of the tumour tissue
while administering the tracer; this is solved by small in-
jection volumes (<0.2 ml) and to slowly pull a little bit
back while administering the tracer. This peri- or intratu-
moural radiopharmacologic administration will result in
extra-axillary SLNs, which, in our institute, are includedfor diagnosis [18]. Prior to surgery, the radiologist localises
the 125I seed by ultrasonic reflection of the titanium cap-
sule in order to place a needle into the tumour. Subse-
quently, a nuclear physician injects the 99mTc-nanocolloid
[19]. This can be a challenging intervention due to diffi-
culties in localising the 125I seed in pathological and ir-
regular breast tissue. Furthermore, the procedure requires
two medical specialists (e.g. a radiologist and a nuclear
physician) and a technologist. By avoiding this additional
US procedure, the workload of the radiology department
will be decreased.
Recently, a novel freehand single-photon emission com-
puted tomography (SPECT) system (declipse®SPECT, Sur-
gicEye GmbH, Munich, Germany) for three-dimensional
(3D) radio-guided imaging and navigation has been in-
troduced. This device combines a conventional gamma
probe with an optical tracking system. An algorithm
links the measured counts from the location of the
gamma probe in space and, accordingly, reconstructs a
3D visualisation [20,21]. The purpose of this study is to
validate 125I seed localisation guided by freehand SPECT
in patients with non-palpable breast cancer in order to
facilitate 99mTc-nanocolloid injections. The results of
this study could also serve as a proof of concept for use




Forty-four patients with a peri-/intratumoural 125I seed
(STM1251, Bard Brachytherapy, Inc., Carol Stream, IL,
USA) and scheduled for an SLN procedure were included.
The patients were included in consecutive order, and in-
clusion was based on availability of researchers, SPECT/
CT scanner and the freehand SPECT device. The study
protocol included a group of patients scheduled for both
US and freehand SPECT (group 1, n = 10) followed by a
second group of patients investigated with only the free-
hand SPECT probe (group 2, n = 34). The results of the
second group were compared with a control group of pa-
tients who had received injections guided by US (group 3,
n = 21). Experienced radiologists measured the tumour
size by means of MRI or mammography. The characteris-
tics of the groups are as follow:
Group 1: In ten patients in the period from October 2012
to December 2012, the location and depth of the 125I seed
were measured using both freehand SPECT and US.
The 99mTc-nanocolloid was injected exactly according
to the standard protocol based on US-guided injec-
tions, which is the technique of choice at the
Netherlands Cancer Institute. The standard protocol
means no additional SPECT/CT scan to limit additional
radiation exposure for patients.
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2013, 34 patients were included. The location and depth
of the 125I seed were measured using freehand
SPECT followed by a freehand SPECT-guided
injection with 99mTc-nanocolloid. These 34 patients
received a SPECT/CT scan to measure the accuracy
of the 99mTc-nanocolloid injection location in relation
to the 125I seed.
Group 3: The control group was constituted
retrospectively by 21 consecutive patients who
underwent US-guided 99mTc-nanocolloid injection near
the 125I seed and a SPECT/CT in the period from April
2012 to March 2013. This means that only those patients
who had received a SPECT/CT in the context of a stan-
dard SLN procedure (i.e. non-visualisation of lymphatic
drainage or aberrant lymphatic drainage on the planar
imaging) were included. This group is selected to study
the US-guided injection depots of 99mTc-nanocolloid by
means of SPECT/CT without making additional SPECT/
CT scans.
The standard clinical SLN protocol
All patients who are to undergo a SLNB get a 99mTc-
nanocolloid (GE Healthcare, Eindhoven, The Netherlands)
injection of 140 MBq in 0.2 ml 1 day prior to surgery.
Five-minute static scintigraphic images are acquired from
the anterior and lateral sides 5 to 30 min and 2 to 3 h
post-injection, respectively. In case of non-visualisation or
aberrant lymphatic drainage, an additional SPECT/CT
scan is obtained. All SPECT/CT data are acquired
using a hybrid camera (Symbia T, Siemens, Erlangen,
Germany). The dual-head SPECT (128 × 128 matrix, 40
frames, 30 s/frame) is performed using 9° angular steps in
a 30-s time frame. For CT (130 kV, 40 mA, B30s kernel),
5-mm slices are obtained. Both attenuation and scatter
correction are applied.
Freehand SPECT acquisition and reconstruction
This method was based on combining counts measured
with a conventional gamma probe with data of the loca-
tion and orientation of the gamma probe using a reflect-
ive reference target attached to a specific site on the
probe. Through a calibration procedure, the relation be-
tween the gamma probe tip and the reference target was
determined [22]. To acquire an accurate 3D volume re-
construction from the count data, a surface scan was
made by hovering the probe over the area of interest in
three different orientations (e.g. x, y and z planes). The
system requires at least 1,500 measurements to accu-
rately create a 3D visualisation; in our protocol, we
adopted thus a minimum of 2,000 measurements in
three or more directions. This planar surface scanning
takes about 2 min, and the reconstruction of the volume
takes another 20 s. After the reconstruction, the opticalcamera of the used system was combined with a radio-
activity map (Figure 1b). The window level was adjusted
by using a touch screen to set a visualisation threshold
similar to the ones used in conventional nuclear medicine
until the number of hot spots equals the number of 125I
seeds in situ. The 3D window enabled the best navigation
to the 125I seed (Figure 1c).
For patients of group 1, the perpendicular distance from
the skin to the 125I seed was determined with the freehand
SPECT, and the most intensive focus in the 3D recon-
struction was marked on the skin of the patient. Next, the
radiologist, who was blinded for the depth information,
localised the 125I seed with US and measured the per-
pendicular depth from the marked place on the skin to
the 125I seed. After which, he injected the 99mTc-nano-
colloid close to the 125I seed. To avoid breast tissue de-
formations, it is important that the patient does not
change position during the freehand SPECT and US
measurements.
For patients of group 2, the perpendicular depth to
the 125I seed, which was used for US-guided injections
as well, was measured per patient, and the optimal injec-
tion location was marked on the skin. The needle was
injected to the depth indicated by the freehand SPECT
(Figure 1c). Three hours after injection of the 99mTc-nano-
colloid, a SPECT/CT scan was obtained. Verification of
the 99mTc-nanocolloid injection relative to the 125I seed
was performed by comparing the 99mTc-nanocolloid depot
on the SPECT images to the location of the 125I seed on
the CT scan. The distance from the 125I seed to the centre
of the activity depot in the axial plane was measured. All
distances on SPECT/CT were once more determined by a
second independent blinded observer to study the limits
of agreement.
Statistics for data analysis
Continuous variables were represented by mean ± stan-
dard deviation (SD). Differences between the measured
depths of the 125I seed by freehand SPECT and US are
evaluated by Bland-Altman graphs. The limits of agree-
ment between the different observers were also evaluated
by Bland-Altman graphs. This results in mean difference
and 95% confidence interval (95% CI) [23].
Results
Group 1: US validation
The characteristics of all ten patients are outlined in
Table 1. The lesions were found on various locations in
the breast. The ten perpendicular measurements with
US and freehand SPECT of the 125I seed resulted in ab-
solute variations in the range from 0 to 5 mm. The ave-
rage difference in depth was 0.05 ± 2.4 mm (range −3.5 to
5 mm), and the absolute average was 1.6 ± 1.6 mm (range
0 to 5 mm). These data are displayed in a Bland-Altman
Figure 1 Freehand SPECT method. (a) Data acquisition using the freehand SPECT device; radioactivity is measured with the probe from
multiple directions. P is the probe, and in yellow, the detection beam of the probe. The orange cloud is an accumulation of the area where it is
measured. (b) The localisation of the 125I seed after reconstruction. The 125I seed reconstruction is projected over the optical image in purple. T is
the patient tracker. (c) 3D visualisation of the distance and direction of the probe tip to the 125I seed. (d) Injection of 99mTc-nanocolloid guided
by freehand SPECT. I is the tracer injection localisation.
Table 1 Patient information for US validation, patient information for SPECT/CT validation and retrospective
US-guided injections
Parameter Group 1, US validation
(n = 10) (SD, range)
Group 2, SPECT validation (n = 34)
(SD, range)
Group 3, retrospective US-guided
injections (n = 21) (SD, range)
Patient age (years) 51 (8.4, 42 to 66) 61.3 (12.1, 26 to 89) 59 (10.6, 42 to 86)
Tumour size (mm) 11.5 (3.1, 9 to 20) 17.1 (13.8, 3 to 60) 18.4 (13.1, 8 to 55)
Tumour type DCIS (n = 3), IDC (n = 6),
ILC (n = 1)
DCIS (n = 12), LCIS (n = 1), IDC (n = 14),
ILC (n = 4), unknown (n = 3)
DCIS (n = 14), LCIS (n = 4),
unknown (n = 3)
Number of 125I seeds 1 with 1 seed (30), with 2 seeds (4) 1
Location of 125I seeds 3 medial, 6 lateral, 1 central 7 medial, 22 lateral, 5 central 5 medial, 13 lateral, 3 central
Days after 125I seed implantation 30 (13, 12 to 56) 33.5 (23.3, 10 to 118) Not measured
125I seed depth by US (mm) 11.6 (6.4, 5 to 23) Not measured Not measured
125I seed depth by freehand SPECT (mm) 11.5 (6.6, 5 to 25) 15.3 (6.7, 8 to 35) Not measured
Difference in localisation or location (mm) Mean difference, 0.05
(2.4, −3.5 to 5)
Absolute mean difference, 1.6 (1.6, 0 to 5) 10.9 (6.8, 0 to 29)
(CT compared with SPECT)
9.7 (6.5, 2 to 30) (CT compared
with SPECT)
Irradical procedures 1/10 (focal irradical) 9/34 (focal irradical or irradical) 5/21 (focal irradical or irradical)
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ.
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deviation ranges [24] (Figure 2).
Group 2: SPECT/CT validation
The characteristics of all 34 patients are outlined in
Table 1. The patients had either one or two 125I seeds
implanted, and the tumours were located on various lo-
cations within the breast. The average distance from the
centre of the 99mTc-nanocolloid depot to the 125I seed
on SPECT/CT was 10.9 ± 6.8 mm (range 0 to 29 mm).
Retrospective analysis of the data showed a possible
relation between the number of measurements made by
the freehand SPECT and the distance between the 99mTc-
nanocolloid injection depot and the 125I seed. In ten injec-
tions, we noticed that the number of measurements was
more than the protocolled 2,000 to 2,500 but was 3,000 to
3,500 measurements at least. We evaluated the differences
to study whether a higher number of measurements will
result in more accurate injections. The ten injections with
more measurements resulted, after measuring the distance
between the 99mTc-nanocolloid injection depot and the 125I
seed, in a mean distance of 10.0 mm instead of 11.2 mm in
the other 26 injections.
Group 3: control group
In the retrospectively selected US-guided 99mTc-nanocol-
loid injections (patient group 3), the distance from the
depot to the 125I seed was 9.7 ± 6.5 mm (range 2 to 30
mm) on SPECT/CT. Comparison of the distance from theFigure 2 Bland-Altman analysis for the distances in depth
measured with US probe and with the freehand SPECT. The
analysis indicates, with the black broken line, the average of the
measurements. The upper and lower red broken lines represent the
Bland-Altman limits within the 95% confidence interval.depot to the 125I seed in the freehand SPECT- (group 2)
and US-guided injections (group 3) revealed no significant
difference (two-sample Student's t test, p = 0.52). This
means there is no difference in accuracy for US-guided
and freehand SPECT-guided injections. The mean diffe-
rence between the two observations in this setting was 0.5
mm (95% CI 2.9 to −3.5 mm); for freehand SPECT-guided
injections, the difference was 0.1 mm (95% CI −3.0 to 3.1
mm), and for the US-guided injections, the difference was
0.9 mm (95% CI −2.2 to 4.0 mm) (Figures 2 and 3). There
are images included in this work that illustrate the loca-
tion of the 125I seed and the 99mTc-nanocolloid depot by a
fusion of the SPECT signal and the CT scan (Figure 4).
In total, 65 peri-/intratumoural 99mTc-nanocolloid injec-
tions were included in this study for analysis. The overall
sentinel node (SN) identification rate was 1.2 SNs/patient,
and 56/65 had SN visualisation on either lymphoscinti-
graphy or SPECT/CT. The intraoperative SN identifica-
tion rate was higher, thanks to prolongation of the time
interval (allowing further lymph drainage) and the use of
blue dye.
Discussion
This study demonstrates that peri-/intratumoural 99mTc-
nanocolloid injections using a freehand SPECT device
are feasible in patients with non-palpable breast cancer
marked with a 125I seed. The freehand SPECT is able to
localise the 125I seed and obtains navigation parameters
for subsequent SLN procedure-related tracer injection.
The manufacturer specified a spatial resolution of 5 mm
for the freehand SPECT, suggesting that this device was
appropriate for the intervention described in our study
[25]. Our results confirmed this by showing a mean dif-
ference of 1.6 ± 1.6 mm (range 0 to 5 mm) compared to
the conventional US technique. Additionally, it was con-
cluded that the concordance of freehand SPECT-guided
administrations compared to US-guided administrations
validated by means of SPECT/CT imaging was clinically
acceptable for the approach that we pursue. This study
was not designed to study a learning curve; we also did
not find a learning curve in this limited number of cases.
This might be the result of varying observers. However,
to use the freehand SPECT device, a training period is
required. The results of this study and the benefits of
using this technique seem to support the use of freehand
SPECT for 125I seed-guided radiocolloid injections in pa-
tients scheduled for SLNB and thereby enhance the lo-
gistics and workload of nuclear medicine and radiology
departments.
Image-guided injections
For SLNB, US-guided injections are commonly used to
deliver 99mTc-nanocolloid into or in the vicinity of the
tumour [19]. In cases where the 125I seed is not identifiable,
Figure 3 Bland-Altman analysis for the interobserver agreement between freehand SPECT-guided and US-guided injections. The
analysis indicates, with the black broken line, the average of the measurements. The upper and lower red broken lines represent the Bland-Altman
limits within the 95% confidence interval.
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tions and the stereotaxic procedures have certain draw-
backs; first of all, the planning is more complicated because
there are two departments involved, and the time per pro-
cedure is variable (15 to 45 min). Furthermore, the locali-
sation of the 125I seed may be time consuming and requires
a radiologist. The injection using freehand SPECT is
straightforward and, as described in the present study,
clinically applicable. The procedure can be performed in
a nuclear medicine department, which does increase theFigure 4 Axial SPECT/CT images. (a) The low-dose CT. (b) The
SPECT and CT images fused. (c) Close-up of the low-dose CT. (d)
The SPECT and CT images fused with the measurement of distance
from the centre of activity of the 99mTc-nanocolloid to the 125I seed;
the measured distance is 8 mm. The green lines indicate the same
position in the different images.flexibility in planning. In our experience, the procedure
never exceeded 20 min, taking, in average, 10 to 15 min.
A second benefit is that this procedure may avoid po-
tential pitfalls in misjudging the identity of the 125I seed
and thereby an incorrect injection location of 99mTc-
nanocolloid in patients with other types of markers in
situ or calcifications in the breast. These other non-
radioactive markers do not affect the freehand SPECT
technique.
The radiocolloid injection site for SLNB is still a matter
of controversy [13,14,16,17]. The freehand SPECT method
as described in this study is only of clinical relevance for
tumour-related tracer administration. For injections in
the vicinity of the tumour, this technique is sufficient.
However, for injections in small lesions, this technique
requires more precision. This could be acquired with an
optically tracked needle integrated in the freehand
SPECT system. There are prototypes of needles or cath-
eters with optical tracking systems, enabling exact nee-
dle tip localisation and thereby possibly more accurate
injections [26]. For the 36 freehand SPECT-guided injec-
tions, we used 15-, 25-, 35-mm needles, and the depth
was determined on the basis of depth estimation.
Optimisation of freehand SPECT
There are several possibilities to explain the observed
distance deviation between the 99mTc-nanocolloid injec-
tion depot and the 125I seed on SPECT/CT. First, the use
of older (weaker in radioactivity) 125I seeds may give sig-
nificantly less signal, which influences the image quality.
Another explanation could be the fact that the freehand
SPECT device indicates a depth and a direction, which are
marked on the skin. The nuclear physician had to inject
exactly similar to this direction, or else larger deviations in
deeper injections would logically be the result. Further
analysis of the relation of depth and inaccuracy hinted to
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accurate injections (correlation of 0.58) (Figure 5). When
only the 125I seeds with a depth of <26 mm are taken into
consideration (25/36 125I seeds), the average distance be-
tween the 99mTc-nanocolloid injection depot and the 125I
seed is 8.2 mm (SD 5.1 mm, range 0 to 20 mm) This is
less than the average distance measured on the SPECT/
CT scans for all US-guided injections (group 2).
The retrospective evaluation of the accuracy in ten in-
jections with higher number of measurements demon-
strated a mean distance of 10.0 mm instead of 11.2 mm in
the first 26 injections; this suggests a favourable relation
to obtain more measurements. With these small numbers,
this is not a significant conclusion. Nevertheless, we rec-
ommend using higher number of measurements, because
more data for the calculations would logically result in
more accurate reconstructions and could, for example,
compensate the weak signal of older 125I seeds. An ad-
ditional source of error in the evaluation might be the
registration between CT and SPECT and the slice thick-
ness of the CT images. These factors can have both posi-
tive and negative impacts on the evaluation but have to be
considered when looking at the standard deviation of the
results.
In the present study, freehand SPECT reconstruction
was based on settings used for standard intraoperative
procedures. In theory, it is possible to increase the num-
ber of iterations or reduce the voxel size. The standard
number of iterations for reconstruction is 20; experimen-
tal settings where the number of iterations rises up to 100
iterations can result in more accurate localisations but
may drastically increase the reconstruction time. The
voxel size is also variable; this can be reduced from 5-
to 2-mm voxels. Experimental setups will be required
in the future to evaluate which are the optimal settingsFigure 5 Distance vs. depth. Distance from 125I seed to the centre
of the 99mTc-nanocolloid activity versus the depth of 125I seed from
the skin.for specific applications. This study also demonstrates
potential use of freehand SPECT for intraoperative 125I
seed localisation since accurate navigation to the radio-
active tumour marker is enabled. Furthermore, the mar-
gins of breast cancer specimens relative to the 125I seed
could be determined ex vivo as predictor for surgical mar-
gins. A prospective study to investigate this assumption is
currently in preparation.
Conclusion
Peri-/intratumoural 99mTc-nanocolloid injection for
SLN mapping using freehand SPECT in patients with
non-palpable breast tumours and implanted 125I seeds
for tumour excision is feasible. This approach may become
a reliable alternative for US-guided 99mTc-nanocolloid in-
jections, alleviating daily/clinical logistics in both nuclear
medicine and radiology departments.
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